Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD7 CAR-T for CD7+ Hematological Malignancies
NCT04599556Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Apr 2021
- Primary completion
- Dec 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD7 CAR-T in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), T-cell non-Hodgkin lymphoma and 1 more (3 arms), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment Emergent Adverse Event at 2 years. Started Apr 2021; status: recruiting.
02
Drugs
anti-CD7 CAR-T
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)T-cell non-Hodgkin lymphomaacute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04599556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599556.